Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2013, vol. 22, nr 6, November-December, p. 899–908

Publication type: review article

Language: English

The Impact of Reactive Oxygen Species on Anticancer Therapeutic Strategies

Wpływ reaktywnych form tlenu na antyrakowe strategie terapeutyczne

Donika Ivanova1,D, Rumiana Bakalova2,3,A,D,E,F, Dessisslava Lazarova2,, Veselina Gadjeva1,D, Zhivko Zhelev1,A,E,F

1 Deparment of Medicinal Chemistry and Biochemistry, Medical Faculty, Trakia University, Stara Zagora, Bulgaria

2 Medical Faculty, Sofia University, Sofia, Bulgaria

3 Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan

Abstract

Over 50 years of experience in free radical biology and medicine shows that normal cells of healthy mammals are characterized by a low steady-state level of reactive oxygen species (ROS) and a constant (reference) level of reducing equivalents. A lasting increase of ROS above the critical level leads to permanent oxidative stress in the cells. This could cause genomic instability and mutations, which are responsible for adaptation of cells to oxidative stress and their survival in an oxidative environment. In turn, these events could provoke malignancy. It is widely accepted that the balance between ROS and reducing equivalents in cells and tissues determines their redox status. The evaluation of tissue redox status has great diagnostic potential in cancer, as well as prognostic potential for cancer therapy, and could significantly contribute to the planning of appropriate treatment and to increasing the patients’ quality of life. The conventional therapeutic strategy is based on drugs that increase ROS generation and induce apoptosis in cancer cells. However, this therapeutic approach has serious disadvantages: the expression of various toxic side effects in normal (non-cancer) tissues. The current review describes the basics of free radical biology in carcinogenesis. The authors emphasize the different redox status of normal and cancer cells, which permits the use of this parameter as a new therapeutic target. The authors also outline some directions for the development of promising therapeutic strategies based on the regulation of redox signaling using combined therapy. The review is intended for a broad readership – from non-specialists to researchers in the field of cancer biochemistry and pharmacy

Key words

cancer; reactive oxygen species, redox signaling, therapy.

References (47)

  1. Kahlos K, Soini Y, Pakko P, Saily M, Linnainmaa K, Kinnula VL: Proliferation, apoptosis, and MnSOD in malignant mesothelioma. Int J Cancer 2000, 88, 37–42.
  2. Caldas C: Molecular assessment of cancer. Br Med J 1998, 316, 1360–1363.
  3. Weinberg F, Chandel NS: Reactive oxygen species – development signaling regulates cancer. Cell Mol Life Sci 2009, 66, 3663–3673.
  4. Weyemi U, Dupuy C: The emerging role of ROS-generating NADPH oxidase NOX4 in DNA-damage responses. Mutat Res 2012, 751, 77–81.
  5. Naka K, Muraguchi T, Hoshii T, Hirao A: Regulation of ROS and genomic stability in hematopoietic stem cells. Antioxid Redox Signal 2008, 10, 1883–1894.
  6. Trachootham D, Alexandre J, Huang P: Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009, 8, 579–591.
  7. Halliwell B, Gutteridge J: Free Radicals in Biology and Medicine, Oxford University Press, 4th Edition, 2007.
  8. Inoue M, Sato EF, Nishikawa M, Park A-M, Kira Y, Imada I, Utsumi K: Mitochondrial generation of ROS and its role in aerobic life. Curr Med Chem 2003, 10, 2495–2505.
  9. West AP, Shadel GS, Ghosh S: Mitochondria in innate immune responses. Nat Rev Immunol 2011, 11, 389–402.
  10. Weyemi U, Lagente-Chevallier O, Boufraqech M, Penois F, Courtin F, Caillou B, Talbot M, Dardalhon M, Ghuzlan AAl, Birdart J-M, Schlumberger M, Dupuy C: ROS-generating NADPH oxidase NOX4 is a critical mediator in oncogenic H-Ras-induced DNA damage and subsequent senescence. Oncogene 2012, 31, 1117–1129.
  11. Bedard K, Krause KH: The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007, 87, 245–313.
  12. Chrissobolis S, Faraci FM: The role of oxidative stress and NADPH oxidase in cerebrovascular disease. Trends Mol Med 2008, 14, 495–502.
  13. Miller FJ, Chu X, Stanic B, Tian X, Sharma RV, Davisson RL, Lamb FS: A differential role for endocytosis in receptor-mediated activation of NOX1. Antioxid Redox Signal 2010, 12, 583–590.
  14. Trachootham D, Lu W, Ogasawara MA, Nilsa RD, Huang P: Redox regulation and cell survival. Antioxid Redox Signal 2008, 10, 1343–1374.
  15. Coleman WB, Tsongalis GJ: Molecular mechanisms of human carcinogenesis. In: Cancer: Cell Structures, Carcinogens and Genomic Instability, Bignold, L.P. (Ed.), Birkhauser Verlag, Switzerland 2006, 321.
  16. Meister M, Tomasovic A, Banning A, Tikkanen R: Mitogen-activated protein (MAP) kinase scaffolding proteins: A recount. Int J Mol Sci 2013, 14, 4854–4884.
  17. Verschoor M, Wilson LA, Singth G: Mechanisms associated with mitochondrial-generated ROS in cancer. Can J Physiol Pharmacol 2010, 88, 204–219.
  18. Chetram MA, Bethea DA, Odero-Marah VA, Don-Salu-Hewage AS, Jones KJ, Hinton CV: ROS-mediated activation of Akt induced apoptosis via pVHL in prostate cancer cells. Mol Cell Biochem 2013, 376, 63–71.
  19. Suzuki K, Matsubara H: Recent advances in p53 research and cancer treatment. J Biomed Biotechnol 2011, art. 978312.
  20. Kagan V, Bakalova R, Karakashev P: Lipid peroxidation in tumor cells and tissues of tumor-bearing animals. In: “Membrane Lipid Oxidation”, Vigo-Pelfrey, C. (Ed.), CRC Press, Boca-Raton, Florida, Vol. III, 1990, 192–208.
  21. Kahlos K, Anttila S, Asikainen T, Kinnula K, Raivio KO, Mattson K, Linnainmaa K, Kinnula VL: Manganese superoxide dismutase in healthy human pleural mesothelium and in malignant pleural mesothelioma. Am J Respir Cell Mol Biol 1998, 18, 570–580.
  22. Amundson SA, Myers TG, Fornace JrAJ: Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene 1998, 17, 3287–3299.
  23. Maiti AK: Genetic determinants of oxidative stress-mediated sensitization of drug-resistant cancer cells. Int J Cancer 2012, 130, 1–9.
  24. Penney RB, Roy D: Thioredoxin-mediated redox regulation of resistance to endocrine therapy in breast cancer. Biochim Biophys Acta 2013, 1836, 60–79.
  25. Zhelev Z, Aoki I, Gadjeva V, Nikolova B, Bakalova R, Saga T: Tissue redox activity as a sensing platform for imaging of cancer based on nitroxide redox cycle. Eur J Cancer 2013, 49, 1467–1478.
  26. Zhelev Z, Gadjeva V, Aoki I, Bakalova R, Saga T: Cell-penetrating nitroxides as molecular sensors for imaging of cancer in vivo, based on tissue redox activity. Mol BioSystems 2012, 8, 2733–2740.
  27. Bakalova R, Zhelev Z, Aoki I, Saga T: Tissue redox activity as a hallmark of carcinogenesis: from early to terminal stage of cancer. Clin Cancer Res 2013, 19, 2503–2517.
  28. Barrera C: Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN Oncology 2012, art. no. 137289.
  29. De Luca A, Sanna F, Sallese M, Ruggiero C, Grossi M, Sacchetta P, Rossi C, De Laurenzi V, Di Ilio C, Favaloro B: Methionine sulfoxide reductase A dawn-regulation in human breast cancer cells results in a more aggressive phenotype. Proc Natl Acad Sci USA 2010, 107, 18628–18633.
  30. Harris IS, Blaser H, Moreno J, Treloar AE, Gorrini C, Sasaki M, Mason JM, Knobbe CB, Rufini A, Halle M, Elia AJ, Wakeham A, Tremblay ML, Melino G, Done S, Mak TW: PTPN12 promotes resistance to oxidative stress and supports tumorogenesis by regulating FOXO signaling. Oncogene 2013, doi: 10.1038/onc.2013.24.
  31. Nonn L, Berggren M, Powis G: Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Mol Cancer Res 2003, 1, 682–690.
  32. Beck R, Dejeans N, Glorieux C, Pedrosa RC, Vasquez D, Valderrama JA, Calderon PB, Verrax J: Molecular vhaperone Hsp90 as a target for oxidant-based anticancer therapy. Curr Med Chem 2011, 18, 2816–2825.
  33. Fong MY, Jin S, Rane M, Singh RK, Gupta R, Kakar SS: withaferin A synergizes the therapeutic effect of doxorubicin through ROS-mediated autophagy in ovarian cancer. PLoS One 2012, 7, e42265.
  34. Sterba M, Popelova O, Vavrova A, Jirkovsky E, Kovarikova P, Gersl V, Simunek T: Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid Redox Signal 2013, 18, 899–929.
  35. Gadjeva V, Koldamova R: Spin-labeled 1-alkyl-1-nitrosourea synergists of antitumor antibiotics. Anti-Cancer Drug Design 2001, 16, 247–253.
  36. Shaaban S, Diestel R, Hinkelmann B, Muthukumar Y, Verma RP, Sasse F, Jacob C: Novel peptidomimetic compounds containing redox active chalcogens and quinones as potential anticancer agents. Eur J Med Chem 2012, 58, 192–205.
  37. Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P: Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 2003, 101, 4098–4104.
  38. Takahashi S: Combination therapy with arsenic trioxide for hematological malignancies. Anticancer Agents Med Chem 2010, 10, 504–510.
  39. Ramanatham B, Jan KY, Chen CH, Hour TC, Yu HJ, Pu YS: Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res 2005, 65, 8455–8460.
  40. Kamada T: Clinical evidence of particle beam therapy (carbon). Int J Clin Oncol 2012, 17, 85–88.
  41. Maiti AK: Elevate the ROS level to kill cancer cells during chemotherapy. Chemotherapy 2012, 1, 5.
  42. Lawenda BD, Kelly KM, Ladas EJ, Sagar SM, Vickers A, Blumberg JB: Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst 2008, 100, 773–783.
  43. Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C: Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer 2008, 123, 1227–1239.
  44. Dimova EG, Bryant PE, Chankova SG: “Adaptive response” – some underlying mechanisms and open questions. Genet Mol Biol 2008, 31.
  45. Dabrowski A, Boquslowicz C, Dabrowska M, Tribillo I, Gabryelewicz A: Reactive oxygen species activate MAPKs in pancreatic acinar cells. Pancreas 2000, 21, 376–384.
  46. Drigotas M, Affolter A, Mann WJ, Brieger J: Reactive oxygen species activation of MAPK pathway results in VEGF up-regulation as an undesired irradiation response. J Oral Pathol Med 2013, E-pub: March 11, doi: 10.1111/ jop.12056.
  47. Grdina DJ, Murley JS, Miller RC, Mauceri HJ, Sutton HG, Li JJ, Woloschak GE, Weichselbaum RR: A surviving-associated adaptive response in radiation therapy. Cancer Res 2013, 73, 4418–4428.